Glenmark Pharma launches anti-epileptic drug, Rufinamide, in the US

The newly launched drug is a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai, Inc. Banzel tablets are used in combination with other medications to treat children with Lennox-Gastaut syndrome, a severe form of childhood epilepsy that also causes developmental and behavior problems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2SO5QcL
via IFTTT